J. Cambronero - Concepedia

Concepedia

Author

J. Cambronero

Hospital Universitario Infanta Leonor ORCID

Also Known As

J. Cambronero, JA Aguirre-Sánchez Cambronero, Javier Cambronero, Jeudy Alonso Cambronero

23

Publications

1.2K

Citations

10

H-Index

18

Concepts

All Affiliations

Hospital Universitario Infanta Leonor Astellas Pharma (Netherlands)Imperial College London University of Toronto Hospital Universitario de Getafe

JC

About

J. Cambronero is an author at Hospital Universitario Infanta Leonor specializing in medicine, urology, and urogynecology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	476
2	Endocrinology	1	1	10
3	Immunology	1	1	10
4	Neuroscience	1	1	10
5	Pharmacology	1	1	416

J. Cambronero

×

10

Publications

1.2K

Citations

10

H-Index

	Year	Citations
Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial Vik Khullar, G. Amarenco, J.C. Angulo, European Urology Urological ResearchUrologyVoiding Dysfunctionβ3-Adrenoceptor AgonistMedicine	2012	416
Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double‐blind, placebo‐controlled, phase <scp>III</scp> studies V. Khullar, Philip E.V. van Kerrebroeck, Sender Herschorn, International Journal of Clinical Practice	2013	206
Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE) Marcus J. Drake, Christopher R. Chapple, Adil Esen, European Urology	2016	181
Radiologic Findings of Segmental Testicular Infarction G. C. Fernández-Pérez, Francisco Tardáguila, María José Martín Velasco, American Journal of Roentgenology	2005	146
The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial José E. Batista, H. Kölbl, Sender Herschorn, Therapeutic Advances in Urology	2015	83
Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial Vik Khullar, J. Cambronero, J.C. Angulo, BMC Urology	2013	69
886 THE EFFICACY AND TOLERABILITY OF MIRABEGRON IN PATIENTS WITH OVERACTIVE BLADDER – RESULTS FROM A EUROPEAN–AUSTRALIAN PHASE III TRIAL V. Khullar, J. Cambronero, Peter Ströberg, European Urology Supplements Urological ResearchUrologyVoiding DysfunctionPharmacotherapyUrogynecology	2011	37
684 Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder (OAB): Post-hoc analysis of a prospective, randomised European-Australian phase III trial Vikram Khullar, J. Cambronero, J.C. Angulo, European Urology Supplements Urological ResearchUrologyVoiding DysfunctionPost-hoc AnalysisPharmacotherapy	2012	13
Is the Adrenal Cortex a Putative Site for the Action of Interleukin-1? J. Cambronero, Fernando Rivas, José I. Borrell, Hormone and Metabolic Research InflammationAdrenal GlandPsychoneuroimmunologyAutoimmune DiseaseAdrenal Cortex	1992	10
Age-related efficacy of the selective ß3-adrenoceptor agonist mirabegron for the treatment of overactive bladder (OAB): pooled analysis of three prospective, randomised Phase III studies in patients aged >= 65 years Vikram Khullar, J. Cambronero, J.C. Angulo, ics.org	2012	10

Page 1